+

NO20030064L - Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X - Google Patents

Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X

Info

Publication number
NO20030064L
NO20030064L NO20030064A NO20030064A NO20030064L NO 20030064 L NO20030064 L NO 20030064L NO 20030064 A NO20030064 A NO 20030064A NO 20030064 A NO20030064 A NO 20030064A NO 20030064 L NO20030064 L NO 20030064L
Authority
NO
Norway
Prior art keywords
syndrome
prevention
development
type
diabetes mellitus
Prior art date
Application number
NO20030064A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030064D0 (no
Inventor
Carlos R Plata-Salaman
Jeffrey Crooke
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of NO20030064D0 publication Critical patent/NO20030064D0/no
Publication of NO20030064L publication Critical patent/NO20030064L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20030064A 2000-07-07 2003-01-06 Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X NO20030064L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21714100P 2000-07-07 2000-07-07
US27002201P 2001-02-20 2001-02-20
PCT/US2001/021404 WO2002003984A2 (fr) 2000-07-07 2001-07-06 Derives anti-convulsion utiles au niveau de la prevention du developpement du diabete sucre type ii et du syndrome x

Publications (2)

Publication Number Publication Date
NO20030064D0 NO20030064D0 (no) 2003-01-06
NO20030064L true NO20030064L (no) 2003-03-06

Family

ID=26911655

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030064A NO20030064L (no) 2000-07-07 2003-01-06 Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X

Country Status (22)

Country Link
US (2) US6852701B2 (fr)
EP (1) EP1309324B1 (fr)
JP (1) JP4920163B2 (fr)
CN (1) CN101404993A (fr)
AR (1) AR032465A1 (fr)
AT (1) ATE320805T1 (fr)
AU (1) AU2001280486A1 (fr)
BR (1) BR0112519A (fr)
CA (1) CA2415093A1 (fr)
DE (1) DE60118206T2 (fr)
DK (1) DK1309324T3 (fr)
ES (1) ES2260261T3 (fr)
HU (1) HUP0302307A3 (fr)
IL (1) IL153713A0 (fr)
MX (1) MXPA03000136A (fr)
MY (1) MY126897A (fr)
NO (1) NO20030064L (fr)
NZ (1) NZ523531A (fr)
PL (1) PL365680A1 (fr)
PT (1) PT1309324E (fr)
RU (1) RU2268720C2 (fr)
WO (1) WO2002003984A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
WO2004050081A1 (fr) * 2002-12-02 2004-06-17 University Of Florida Traitements pour tumeurs benignes, cancers, neoplasies, et/ou tout(e) autre trouble ou maladie inflammatoires
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ES2310366T3 (es) * 2004-08-24 2009-01-01 Janssen Pharmaceutica Nv Nuevos derivados de heteroaril sulfonamida benzo-condensada utiles como agentes anticonvulsivos.
MX2007014613A (es) * 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
CN101553204B (zh) * 2006-12-04 2013-10-30 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
WO2008089521A1 (fr) 2007-01-25 2008-07-31 Verva Pharmaceuticals Ltd Sensibilisateurs a l'iinsuline et procédés de traitement
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
US9457008B2 (en) 2012-03-23 2016-10-04 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Joint product comprising synephrine and topiramate
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
BR9710994A (pt) * 1996-06-28 2000-10-24 Ortho Mcneil Pharm Inc Derivados anticonvulsivos úteis no tratamento de obesidade.
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
AU779248B2 (en) 1999-02-24 2005-01-13 University Of Cincinnati, The Use of sulfamate derivatives for treating impulse control disorders
MXPA01010218A (es) * 1999-04-08 2002-03-27 Johnson & Johnson Derivados anticonvulsivos utiles para disminuir lipidos.
WO2000061140A1 (fr) 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Derives anticonvulsivants utiles pour entretenir une perte de poids
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
DE60035870T2 (de) * 1999-06-14 2008-05-08 Vivus Inc., Mountain View Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung

Also Published As

Publication number Publication date
MY126897A (en) 2006-10-31
US20040209824A1 (en) 2004-10-21
NO20030064D0 (no) 2003-01-06
BR0112519A (pt) 2004-03-30
JP2004510700A (ja) 2004-04-08
CA2415093A1 (fr) 2002-01-17
IL153713A0 (en) 2003-07-06
DE60118206T2 (de) 2006-12-14
CN101404993A (zh) 2009-04-08
AU2001280486A1 (en) 2002-01-21
DK1309324T3 (da) 2006-06-12
US6852701B2 (en) 2005-02-08
DE60118206D1 (de) 2006-05-11
HUP0302307A2 (hu) 2003-10-28
US7109174B2 (en) 2006-09-19
WO2002003984A2 (fr) 2002-01-17
EP1309324A2 (fr) 2003-05-14
NZ523531A (en) 2005-07-29
PT1309324E (pt) 2006-06-30
EP1309324B1 (fr) 2006-03-22
US20020037861A1 (en) 2002-03-28
ES2260261T3 (es) 2006-11-01
ATE320805T1 (de) 2006-04-15
WO2002003984A3 (fr) 2003-03-06
JP4920163B2 (ja) 2012-04-18
PL365680A1 (en) 2005-01-10
HUP0302307A3 (en) 2007-05-29
RU2268720C2 (ru) 2006-01-27
AR032465A1 (es) 2003-11-12
MXPA03000136A (es) 2004-09-13

Similar Documents

Publication Publication Date Title
NO20030064D0 (no) Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X
WO2002064210A3 (fr) Polytherapie comprenant des agents antidiabetiques et anticonvulsifs
AU2001283160A1 (en) Cpu accessing an extended register set in an extended register mode
AU4326700A (en) Detection of chemicals using photo-induced and thermal bending in mems sensors
NO20023566D0 (no) Propionsyrederivater og deres anvendelse ved behandling av sukkkersyke og fedme
DK1210380T3 (da) Sammenfoldelige oftalmiske og otorhinolaryngologiske anordningsmaterialer
ATE458718T1 (de) Alpha-cyanoacrylate
AU2002225356A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
AU2003261935A1 (en) Furan or thiophene derivative and medicinal use thereof
NO20011196D0 (no) Raffinærskivesensor og sensorraffinærskive
AU2003258997A1 (en) Dram supporting different burst-length accesses without changing the burst length setting in the mode register
AU2002230544A1 (en) Capacitance probe and spacer therefor
DE60137810D1 (de) Flüssigkristallverbindungen, Flüssigkristallmedium und Flüssigkristallanzeige
NO20030034L (no) En kombinasjon av FBPase-inhibitorer og antidiabetiske midler anvendbare for behandling av diabetes
NO20030800L (no) Aminoalkylbenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte forderes fremstilling og preparater inneholdende de samme
NO20030882L (no) Glasskeramikkmasse og anvendelse derav
AU2001242391A1 (en) Column for counter-currently contacting gas and liquid
DE50112350D1 (de) Arzneimittel enthaltend aktiviertes antithrombin iii
DK1173436T3 (da) Thiazolidindionderivat og anvendelse deraf som antidiabetikum
ATE317386T1 (de) Dihydroindol- und tetrahydrochinolinderivate
AU2001241709A1 (en) Molecules for disease detection and treatment
AU2001237007A1 (en) Integrating electronic and traditional retail
AU2002239543A1 (en) Molecules for disease detection and treatment
AU4471501A (en) Detection film and optical sensor using detection film
NO20015519D0 (no) Farmasöytisk sammensetning omfattende apokodein og/eller dets derivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载